Is It Safe to Give NAD+ to a Dog on Heart Medication?

By Patricia Perkins, DVM, CVA, CVCH, CAC, BHS

✓ Medically reviewed by Patricia Perkins, DVM, CVA, CVCH, CAC, BHS — August 31, 2026 For general education — not a substitute for veterinary care.

Longevity & NAD+ · August 30, 2026 · 5 min read

The honest answer is not a flat yes or no — it depends on the drug, the dose, and whether your cardiologist knows the supplement exists.

A twelve-year-old dachshund named nothing in particular — just “the old man” to his owner — had been on pimobendan and furosemide for eighteen months when the owner asked her vet about adding an NAD+ chew for his stiffening back end. He weighed 19 pounds, was three years into a mitral valve disease diagnosis, and his owner had read that nicotinamide riboside “supports cellular energy.” The question wasn’t whether NAD+ precursors are dangerous in general. The question was whether they’re safe to stack on a heart that’s already being chemically managed.

The short answer: there’s no published evidence that nicotinamide riboside or NMN directly interacts with pimobendan, furosemide, spironolactone, or ACE inhibitors in dogs. There’s also no published safety study in dogs with diagnosed cardiac disease. Absence of a known interaction is not the same as proof of safety, and that gap is where the real decision lives.

The checklist before you add anything

• Confirm the diagnosis and current regimen with your vet — mitral valve disease, dilated cardiomyopathy, and arrhythmias are managed differently, and that changes the risk calculus.
• Ask about kidney values. Furosemide stresses the kidneys, and NAD+ precursors are cleared renally; a dog with borderline kidney function needs bloodwork before, not after.
• Check for GI or appetite side effects in the first two weeks — the most commonly reported reactions to NR-type supplements in dogs are mild nausea or reduced appetite, not cardiac events, but appetite loss in a heart patient is its own red flag.
• Start low, watch closely, and don’t stack multiple new supplements at once — if something changes, you want to know which product caused it.
• Disclose the supplement to whoever manages the cardiac protocol, not just the general practice vet, especially if a cardiologist is titrating diuretic doses.

Each of those points earns its place because it maps to something a whole-body exam would actually catch — not a hypothetical.

What NAD+ precursors are actually doing in an older dog

Nicotinamide riboside is a precursor the body converts into NAD+, a coenzyme cells need for basic energy metabolism. It doesn’t act on the heart the way pimobendan or furosemide does — it isn’t a diuretic, an inotrope, or a vasodilator — so the interaction risk isn’t the classic drug-on-drug kind. The concern is more indirect: an aging heart patient is often also managing kidney workload, appetite, and hydration status, and any new supplement changes the picture your vet is monitoring. A human clinical trial examined the National Library of Medicine (PubMed): safety and tolerability of nicotinamide riboside in patients with heart failure and found it reasonably well tolerated in that population — a meaningfully different species and dosing context than a dog on pimobendan, but it’s the closest real data point available, and it doesn’t show a red flag for combining NR with standard heart-failure drug classes.

I keep coming back to the musculoskeletal exam when I think through cases like this, because a cardiac patient rarely presents with just a cardiac problem. The same dog losing muscle mass from age is often the dog with early arthritis change in the hips and spine, and a slower gait can be heart-related fatigue, joint pain, or both at once. That’s the whole-body picture I try to build before adding anything new: heart, kidneys, joints, appetite, and energy, read together rather than one at a time. A supplement that “supports cellular function” in isolation tells you very little about a dog whose heart, kidneys, and joints are all compensating for each other.

The counterargument I take seriously

The strongest argument for adding NAD+ precursors anyway is that cellular energy decline is a real, measurable part of aging, and a dog with heart disease is already fighting an uphill metabolic battle — so why not support the underlying cell biology while the cardiologist manages the plumbing? That’s not a fringe position. Some owners report better energy and appetite in dogs already on cardiac meds, and one owner survey of a longevity-chew brand recorded high rates of perceived improvement in energy and cognition after supplementation. I take that seriously as anecdote, not as proof, because none of it isolates a heart-medication interaction specifically, and survey data collected by a supplement seller isn’t a substitute for a controlled trial in cardiac patients.

Where I land: I don’t tell owners of stable cardiac patients that NAD+ precursors are off the table. I tell them it’s a three-way conversation between the owner, the primary vet, and the cardiologist if there is one, before the first chew goes in the bowl.

Where the checklist gets complicated in practice

Not every cardiac case is stable, and that’s where a clean checklist stops being clean. A ten-year-old boxer with early dilated cardiomyopathy started an NAD+ chew alongside pimobendan without telling her cardiologist, and by day 12 her owner noticed reduced appetite and a slight increase in resting respiratory rate — both classic early signs of worsening heart failure, not necessarily supplement side effects. Untangling the two took a recheck exam, a chest film, and a frank conversation about stopping the new chew as a control variable. Nothing pointed conclusively at the supplement. But the two weeks of uncertainty, and the delay in adjusting her diuretic if that had been needed, are exactly the cost of adding a variable without disclosure.

An edge case that changes the math

The calculus shifts hard for a dog on chronic NSAIDs or an ACE inhibitor for concurrent kidney protection alongside heart drugs — a fairly common combination in dogs over ten. A 45-pound retriever mix on both benazepril and a joint NSAID for hip arthritis is already carrying real renal workload; NAD+ precursors are cleared through the kidneys, giving the vet one more variable to track in an organ system that’s already stretched. In that dog, “start low and watch closely” isn’t a soft suggestion — it means a recheck kidney panel at three to four weeks, not just a phone check-in. The PetMD: NASC quality seal is one useful filter for product quality and manufacturing oversight, but it says nothing about whether a specific supplement is appropriate for a specific dog’s kidney or cardiac status — that judgment still belongs to the vet who can see the labwork.

If you want the underlying biology in more depth before deciding, our explainer on NAD+ booster safety walks through what the ingredient does outside the cardiac-specific question, and our review of the current evidence covers what’s actually been studied versus marketed. For dosing mechanics once a vet has cleared it, our nicotinamide riboside dosing guide breaks down how dose typically scales with body weight.

Where this leaves you

Nicotinamide riboside isn’t known to interact directly with pimobendan, furosemide, or the other standard cardiac drugs, and the human heart-failure safety data is at least reassuring in direction. But a dog on heart medication is rarely managing just one system, and the same exam that reads the heart should read the kidneys, the joints, and the appetite before anything new goes in the bowl. Disclose it, dose it low, and give it three to four weeks of close watching before deciding it helped.